Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up After Strong Earnings

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) gapped up before the market opened on Thursday following a stronger than expected earnings report. The stock had previously closed at $45.30, but opened at $55.36. Zealand Pharma A/S shares last traded at $55.36, with a volume of 580 shares.

The company reported ($0.87) earnings per share for the quarter, beating the consensus estimate of ($1.37) by $0.50. Zealand Pharma A/S had a return on equity of 48.10% and a net margin of 70.06%.

Analyst Ratings Changes

Several equities research analysts recently weighed in on ZLDPF shares. BNP Paribas Exane downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, March 6th. William Blair reiterated a “market perform” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. Three equities research analysts have rated the stock with a Strong Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy”.

Zealand Pharma A/S Price Performance

The company has a market capitalization of $3.92 billion, a price-to-earnings ratio of 4.01 and a beta of 0.87. The company has a debt-to-equity ratio of 0.02, a quick ratio of 23.57 and a current ratio of 23.57. The business has a 50 day moving average price of $46.66 and a 200-day moving average price of $63.01.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.